Abstract
Canagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers the renal threshold for glucose, resulting in a greatly increased urinary glucose excretion and reduced blood glucose concentrations in patients with hyperglycaemia. This group of drugs has been used as monotherapy and as an adjunct therapy to all antidiabetic drugs. The present review evaluates the concept, therapeutic potential and limitations of canagliflozin as potential antidiabetic agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Research in Medical Education & Ethics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
